Results 21 to 30 of about 3,063 (143)

Baricitinib decreases anti-dsDNA in patients with systemic lupus erythematosus: results from a phase II double-blind, randomized, placebo-controlled trial

Arthritis Research & Therapy, 2022
Background Patients with systemic lupus erythematosus (SLE) have substantial unmet medical need. Baricitinib is a Janus kinase (JAK)1 and 2 inhibitor that was shown to have therapeutic benefit in patients with SLE in a phase II clinical trial.
Thomas Dörner, Ronald F. van Vollenhoven, Andrea Doria, Bochao Jia, Jorge A. Ross Terres, Maria E. Silk, Stephanie de Bono, Peter Fischer, Daniel J. Wallace   +8 more
doaj   +1 more source

Baricitinib as Treatment Option for Corona Virus Disease-19: a Literature Review

Jurnal Kedokteran Diponegoro, 2022
Background : Treatment of COVID-19 using IL-6 inhibitors, including Sarilumab or Tocilizumab, significantly decreased mortality risk. Though, Remdesivir therapy gave benefits, morbidity and mortality remained high.
Thomas Handoyo, Nur Farhanah, Gianina Dinda Pamungkas   +2 more
doaj   +1 more source

Evaluation of VTE, MACE, and Serious Infections Among Patients with RA Treated with Baricitinib Compared to TNFi: A Multi-Database Study of Patients in Routine Care Using Disease Registries and Claims Databases

Rheumatology and Therapy, 2022
Introduction The aim of this work is to evaluate baricitinib safety with respect to venous thromboembolism (VTE), major adverse cardiovascular events (MACE), and serious infection relative to tumor necrosis factor inhibitors (TNFi) in patients with ...
Claudia A. Salinas, Anthony Louder, Jennifer Polinski, Tancy C. Zhang, Hannah Bower, Syd Phillips, Yufei Song, Emaan Rashidi, Rafia Bosan, Hsiu-Ching Chang, Nicole Foster, Bernice Gershenson, Hisashi Yamanaka, Mitsumasa Kishimoto, Yoshiya Tanaka, Peter Fischer, Baojin Zhu, Douglas Faries, Xiaodan Mai, Brett T. Doherty, Angela Grelaud, Nicolas H. Thurin, Johan Askling, Walter Deberdt, the B023 Study Consortium   +24 more
doaj   +1 more source

Real-Life Advantages and Limits of Baricitinib for the Late Treatment of Adults Hospitalized with COVID-19

BioMed, 2023
Baricitinib, a reversible Janus-associated kinase-inhibitor, is approved for treating COVID-19, combined with Dexamethasone and, eventually, with Remdesivir (RDV).
Mariacristina Poliseno, Donato Lacedonia, Mariangela Niglio, Federica De Gregorio, Graziano Antonio Minafra, Terence Campanino, Giulio Giganti, Giulia Scioscia, Teresa Antonia Santantonio, Maria Pia Foschino Barbaro, Sergio Lo Caputo   +10 more
doaj   +1 more source

Baricitinib inhibits structural joint damage progression in patients with rheumatoid arthritis—a comprehensive review

Arthritis Research & Therapy, 2021
Baricitinib is an oral selective inhibitor of Janus kinase (JAK)1 and JAK2 that has proved effective and well tolerated in the treatment of rheumatoid arthritis (RA) in an extensive programme of clinical studies of patients with moderate-to-severe ...
Paul Emery, Patrick Durez, Axel J. Hueber, Inmaculada de la Torre, Esbjörn Larsson, Thorsten Holzkämper, Yoshiya Tanaka   +6 more
doaj   +1 more source

Baricitinib and primary biliary cholangitis

, 2021
Background and aims: There is an unmet need for alternative treatments for patients with primary biliary cholangitis (PBC) who do not respond to treatment with ursodeoxycholic acid (UDCA).
Sujatro Chakladar, Klaus Gottlieb, Ana Pinto-Correia, Doug Schlichting, Stuart C. Gordon, Sheri Trudeau, Arie Regev, Jonathan M. Uhas   +7 more
core   +1 more source

Baricitinib exposure during pregnancy in rheumatoid arthritis [PDF]

, 2020
We here describe the case of a 43-year-old White woman who was diagnosed with rheumatoid arthritis treated with anti-tumour necrosis factor drugs that caused an adverse drug reaction. The objective of this study was to describe the outcome of a pregnancy
Davide Firinu, Firinu D., Losa F., Del Giacco S., Stefano Del Giacco, Margherita Deidda, Maria P. Barca, Giulia Costanzo, Costanzo G., Deidda M., Francesca Losa, Barca M. P.   +11 more
core   +1 more source

EFFICACY OF BARICITINIB IN PATIENTS TREATED WITH CORTICOSTEROIDS FOR SEVERE COVID-19 PNEUMONIA: A RETROSPECTIVE OBSERVATIONAL COHORT STUDY

International Journal of Infectious Diseases, 2023
Intro: Current evidence is still lacking in use of baricitinib among COVID-19 patients that require low flow oxygen and have systemic inflammation. Therefore, we are keen to evaluate the efficacy of baricitinib therapy among this group of patients, in ...
K.H. Tay, L.H. Benedict Sim, S.K. Chidambaram   +2 more
doaj   +1 more source

Baricitinib treatment rapidly improves the four signs of atopic dermatitis assessed by Eczema Area and Severity Index (EASI) clinical subscores. [PDF]

, 2023
BACKGROUND Baricitinib treatment in adults with moderate-to-severe atopic dermatitis (AD) has demonstrated rapid improvements in itch as well as AD sign severity and affected body surface area as assessed by the Eczema Area and Severity Index (EASI ...
Kulthanan, K, Simon, D, Tangsirisap, Nithi, Spina, Lara, Lu, Na, Figueras‐Nart, Ignasi, Kulthanan, Kanokvalai, Grond, Susanne, Wollenberg, Andreas, Wollenberg, A, Eyerich, K,, Figueras-Nart, Ignasi, Grond, Sussanne, Misery, Laurent, Lu, N, Misery, L, Figueras-Nart, I, Spina, L, Grond, S, Tangsirisap, N, Simon, Dagmar, Eyerich, Kilian   +21 more
core   +2 more sources

Impact of the Addition of Baricitinib to Standard of Care Including Tocilizumab and Corticosteroids on Mortality and Safety in Severe COVID-19

Frontiers in Medicine, 2021
Background: Baricitinib is a Janus kinase (JAK) inhibitor with a broader anti-inflammatory activity than tocilizumab and an antiviral potential although no head-to-head trials are available.
Mar Masiá, Sergio Padilla, José Alberto García, Javier García-Abellán, Andrés Navarro, Lucía Guillén, Guillermo Telenti, Paula Mascarell, Ángela Botella, Félix Gutiérrez   +9 more
doaj   +1 more source